Research & Development
Solving the science of global health
Advanced Chemistry, Biological Engineering, and Patient-Centric Formulations.
We engineer non-infringing synthetic routes, discover breakthrough New Chemical Entities (NCEs), and pioneer sustainable manufacturing.
A legacy of global intellectual property
Total Patents Filed
911
Cumulatively Granted
359
Active Global Patents
179
Our core R&D capabilities
Intelligent Process Research & Process engineering for small molecule APIs
We bypass traditional market entry barriers by engineering highly efficient, novel synthetic pathways that do not infringe on competitor IP.
End-to-end NCE discovery
A proven discovery engine dedicated to combating the global crisis of Antimicrobial Resistance (AMR).
Enmetazobactam
Our flagship indigenously discovered novel β-lactamase inhibitor with SFDA, EMA and PMRA approvals. Protected by a patent thicket of active global patents.
Pipeline Momentum
We are rapidly advancing investigational NCEs, including OCID-18483 (Phase-1 trials), which is fully protected by global IP and targets severe gram-negative bacteria (ESBLs, KPCs, MBLs) with a strong safety profile
Peptide Synthesis & CDMO
State-of-the-art cGMP facility delivering custom peptide engineering from discovery to commercial scale.
Complex Engineering
Custom designs incorporating N-methyl amino acids, cyclic peptides, and task-specific ADC linkers.
Precision Technology
Equipped with Hanbon DAC preparative HPLC (up to 600 mL/min) and advanced SP Hull LyoStar 4.0 freeze-drying platforms.
Flexible Models
Discovery-mode R&D, FTE (Fee-for-Service FFS), and full CDMO partnerships.
Innovative formulations
Engineering advanced, multi-modal therapies that combine synergistic ingredients into single, highly stable dosage formats.
Reduced Pill Fatigue
Strategic combination therapies to maximise patient compliance and clinical outcomes.
Optimized Bioavailability
Utilizing highly active derivatives (e.g., Methylcobalamin) for immediate physiological utilization.
Advanced Stacking
Nootropic quad-formulations that carefully pair pharmacokinetics (e.g., L-Theanine + Natural Caffeine) for smooth, sustained absorption.
Green engineering
Systematically reducing our environmental footprint while driving down the overall cost of API production to create resilient supply chains.
Circular Resource Recovery
Closed-loop systems recover unreacted reagents and complex by-products (MBTH, TPPO, MMD) to commercial-grade purity for direct re-usage, drastically minimizing ETP load.
Enzymatic Catalysis
Transitioning away from harsh traditional methodologies to highly efficient, recyclable enzymatic alternatives.
Precision Process Design
Utilizing exact stoichiometric quantities during synthesis to prevent resource over-utilization and keep commercial scale-up highly cost-competitive.
Expanding the frontiers of pharmaceutical science
7-ACA fermentation & biotechnology
Transitioning from synthetic chemistry into advanced biological engineering.
1,000 MTPA Capacity: Establishing a state-of-the-art manufacturing facility in Jammu.
End-to-End Biological Control: Proprietary microbial fermentation of Cephalosporium acremonium and sophisticated enzymatic cleavage to isolate highly pure 7-ACA.
ORAMS: digital antimicrobial stewardship
Bridging the gap between data driven decision making and bedside prescription practices to combat AMR.
Point-of-Care Decision Support: An advanced digital app integrating hospital antibiogram data directly into clinical workflows.
Data Driven Prescription: Digitally tracks antimicrobiotic use, supporting empiric therapy with data driven insights.
